| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 30.24 | 17.7% | 20.4% |
| Total Income | 30.24 | 17.7% | 20.4% |
| Expenditure | 34.78 | 18.0% | 38.6% |
| PBT | — | ||
| Net Profit | 63.86 | 328.0% | 196.1% |
| OPM | -15.03% | 50.01pp | |
| NPM | 100.00% | ||
| EPS | 2.00 | 300.0% | 164.9% |
Agenus Reports Q3 2025 Results: Clinical and Regulatory Advances
04 May 2026 · 4 May, 7:32 am
Summary
Agenus Inc. reported its Q3 2025 results, highlighting clinical and regulatory advancements. France authorized reimbursed compassionate access for BOT/BAL, marking the first government-funded access for this population. Updated Phase 1b results in over 400 patients demonstrated 39% two-year OS across more than five refractory cancers. The global Phase 3 BATTMAN trial is launching in Q4 2025 to evaluate BOT/BAL versus best supportive care in refractory colorectal cancer.
Key Highlights
- 1
Agenus reported Q3 2025 results showcasing clinical and regulatory advances.
- 2
France granted reimbursed access for botensilimab plus balstilimab (BOT/BAL), with patients having commenced treatment.
- 3
Two-year BOT/BAL survival data was presented at ESMO, spanning more than five cancers in over 400 patients.
- 4
The Phase 3 BATTMAN trial is on track to commence in the fourth quarter of 2025.
- 5
In MSS metastatic colorectal cancer patients, BOT/BAL achieved 42% two-year overall survival (OS) and 20.9-month median OS.
- 6
Agenus and Zydus agreed to a $10 million bridge facility ahead of the anticipated $91 million upon closing of the transaction.
Informational and educational content only. Not investment advice.